Endocrine Cancer
Conference Coverage
ATA risk stratification for DTC performs well in real-world cohort
NEW ORLEANS – The risk stratification system also worked well as a predictor of disease-specific survival.
From the Journals
PCOS linked to increased cancer risk in premenopausal women
The increased risks appear to subside after menopause.
From the Journals
CTCs linked to late recurrence in HER2–, HR+ breast cancer
Study is the first to show that this CTC assay may play a role in determining late clinical recurrence after local and systemic adjuvant therapy...
Conference Coverage
U.S. pancreatic insufficiency patients often get inadequate enzyme replacement
U.S. insurance claims data during 2006-2013 show that patients with presumed exocrine pancreatic insufficiency often go undertreated.
Conference Coverage
Pancreatic cancer has a pancreatopathy distinct from type 2 diabetes
WASHINGTON – The relationship between pancreatic cancer and diabetes is complex, but certain pathological markers differentiate them.
Conference Coverage
Diabetes from checkpoint inhibitors probably means lifelong insulin
CHICAGO – In the largest case series to date, almost all patients remained on insulin at a median follow-up of 44 weeks, even after stopping ICIs...
Conference Coverage
New and improved classifiers may sharpen thyroid nodule diagnosis
VICTORIA, B.C. – The tests could improve preoperative assessment, even in histologic subsets that pose diagnostic challenges.
Conference Coverage
Cancer patients with TKI-induced hypothyroidism had better survival rates
When it comes to the adverse effects of tyrosine kinase inhibitors, hypothyroidism appears to have a bright side.
Conference Coverage
Calcitonin-to-CEA ratio predicts medullary thyroid cancer survival
Can a ratio of serum calcitonin to carcinoembryonic antigen predict survival in patients with medullary thyroid cancer?
Conference Coverage
Big changes coming for thyroid cancer staging
How big an impact will new thyroid staging criteria have on the numbers of stage I disease? It’ll be huge.
Conference Coverage
Contralateral nodal thyroid metastases show slow progression
BOSTON – In some thyroid cancers, a small level III contralateral nodal metastasis may be watched safely rather than resected.